Status:
COMPLETED
COMT Polymorphism and Entacapone Efficacy
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity determined by a geneti...
Detailed Description
COMT protein is dependent of a single autosomal locus with two co-dominant alleles with a high activity (allele H) and a low activity (allele L) form of the enzyme. L and H allele frequency in the Cau...
Eligibility Criteria
Inclusion
- Parkinson's disease
- wearing off
Exclusion
- atypical parkinsonism
- neuroleptic use
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00373087
Start Date
October 1 2006
End Date
November 1 2009
Last Update
April 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre d'Investigation Clinique, Hôpital de la Pitié-Salpétrière,
Paris, France, 75013